JW (Cayman) Therapeutics Co. Ltd. (HK:2126)
:2126
Want to see HK:2126 full AI Analyst Report?
2126 Stock Chart & Stats
HK$2.50
-HK$0.02(-1.56%)
At close: 4:00 PM EST
HK$2.50
-HK$0.02(-1.56%)
Day’s Range― - ―
52-Week RangeHK$1.70 - HK$6.44
Previous CloseN/A
Volume104.00K
Average Volume (3M)2.67M
Market Cap
HK$737.61M
Enterprise ValueHK$471.66M
Total Cash (Recent Filing)HK$503.28M
Total Debt (Recent Filing)HK$262.67M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding416,729,430
10 Day Avg. Volume1,852,649
30 Day Avg. Volume2,667,300
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.68
Price to Sales (P/S)3.39
P/FCF Ratio-11.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.77
Revenue Forecast (FY)HK$312.38M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Margin ImprovementA 55% revenue rebound and ~43% gross margin in 2025 indicate growing commercial traction for the company’s cell‑therapy offerings. Sustained top‑line expansion with higher gross margins supports scalability and a clearer path to narrowing losses if product adoption continues.
Improving Operating Cash Flow / Lower Cash BurnMaterial improvement in operating cash flow (from roughly -333M to -77M) reflects better cost control and/or working capital dynamics. If this trend persists it meaningfully extends runway, reduces near‑term financing needs and demonstrates operational leverage coming through as revenues scale.
Moderate Leverage On Balance SheetDebt-to-equity near 0.47 suggests the company is not heavily levered, lowering fixed‑charge risk. Moderate leverage preserves flexibility to fund R&D or commercialization via debt or partnerships and reduces near‑term default risk versus highly indebted peers in biotech cycles.
Bears Say
Persistent Large Operating LossesNet margin around -196% and negative EBIT/EBITDA show losses are deep and persistent. Such structural unprofitability erodes reserves, forces ongoing external financing, and constrains reinvestment; until profitability is consistently achieved, business sustainability remains uncertain.
Ongoing Negative Cash GenerationChronic negative operating and free cash flow means the company depends on external capital to finance operations and growth. Continued reliance on markets or dilution risks limiting strategic options and could slow development/commercial rollouts if funding conditions tighten.
Equity Erosion And Weakened Capital BaseMaterial declines in equity from prior years reflect cumulative losses that shrink the capital buffer. A weakened capital base reduces financial resilience, may raise borrowing costs, and increases the likelihood of future dilution as the company raises funds to support development and commercialization.
JW (Cayman) Therapeutics Co. Ltd. News
2126 FAQ
What was JW (Cayman) Therapeutics Co. Ltd.’s price range in the past 12 months?
JW (Cayman) Therapeutics Co. Ltd. lowest stock price was HK$1.70 and its highest was HK$6.44 in the past 12 months.
What is JW (Cayman) Therapeutics Co. Ltd.’s market cap?
JW (Cayman) Therapeutics Co. Ltd.’s market cap is HK$737.61M.
When is JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date?
JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 81 days.
How were JW (Cayman) Therapeutics Co. Ltd.’s earnings last quarter?
JW (Cayman) Therapeutics Co. Ltd. released its earnings results on Mar 26, 2026. The company reported -HK$0.758 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.758.
Is JW (Cayman) Therapeutics Co. Ltd. overvalued?
According to Wall Street analysts JW (Cayman) Therapeutics Co. Ltd.’s price is currently Overvalued.
Does JW (Cayman) Therapeutics Co. Ltd. pay dividends?
JW (Cayman) Therapeutics Co. Ltd. does not currently pay dividends.
What is JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate?
JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JW (Cayman) Therapeutics Co. Ltd. have?
JW (Cayman) Therapeutics Co. Ltd. has 416,729,430 shares outstanding.
What happened to JW (Cayman) Therapeutics Co. Ltd.’s price movement after its last earnings report?
JW (Cayman) Therapeutics Co. Ltd. reported an EPS of -HK$0.758 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.124%.
Which hedge fund is a major shareholder of JW (Cayman) Therapeutics Co. Ltd.?
Currently, no hedge funds are holding shares in HK:2126
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JW (Cayman) Therapeutics Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
133.33%
12-Months-Change
Fundamentals
Return on Equity
-75.15%
Trailing 12-Months
Asset Growth
-38.53%
Trailing 12-Months
Company Description
JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company dedicated to the development, manufacture, and commercialization of cell-based immunotherapies. The company primarily targets hematological cancers and solid tumors through treatments that harness the body's own immune cells to combat disease, notably including CAR-T therapies. Its leading therapeutic candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy designed to treat a variety of blood cancers. The company's innovative pipeline also features JWCAR129, an autologous CAR-T therapy for multiple myeloma; JWATM204, a TCR T-cell therapy candidate aimed at hepatocellular carcinoma (HCC); and JWATM203, another autologous T-cell receptor mimic therapy specifically targeting alpha-fetoprotein for HCC. Founded in 2016, JW (Cayman) Therapeutics Co. Ltd is headquartered in Shanghai, People's Republic of China.
Technical Analysis
Alphamab Oncology
―
CARsgen Therapeutics Holdings Ltd.
―
Mabpharm Limited
―
CStone Pharmaceuticals
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―
Options Prices
Currently, No data available
---